aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $19.00.
A number of analysts have recently weighed in on the company. Roth Capital reissued a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of aTyr Pharma in a report on Friday, March 10th. Piper Sandler upped their price objective on aTyr Pharma from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, April 11th. Roth Mkm reissued a “buy” rating and issued a $9.00 target price on shares of aTyr Pharma in a research report on Monday, March 6th. Finally, StockNews.com began coverage on aTyr Pharma in a research report on Thursday, May 18th. They issued a “hold” rating on the stock.
Insider Buying and Selling
In other aTyr Pharma news, Director Paul Schimmel bought 200,000 shares of the firm’s stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $450,000.00. Following the completion of the purchase, the director now owns 313,023 shares of the company’s stock, valued at $704,301.75. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 3.14% of the company’s stock.
Institutional Investors Weigh In On aTyr Pharma
aTyr Pharma Trading Down 4.3 %
Shares of LIFE stock opened at $2.36 on Friday. aTyr Pharma has a 1 year low of $1.55 and a 1 year high of $4.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.75 and a quick ratio of 8.75. The stock’s 50 day simple moving average is $2.10 and its two-hundred day simple moving average is $2.18. The company has a market cap of $128.12 million, a PE ratio of -1.63 and a beta of 1.21.
aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings data on Thursday, March 9th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.22. The firm had revenue of $10.39 million during the quarter, compared to the consensus estimate of $1.50 million. Research analysts predict that aTyr Pharma will post -1.46 earnings per share for the current year.
aTyr Pharma Company Profile
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.